Read More Pharma Industry News Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA) Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean. bySoujanya RaviMarch 7, 2026